Three Receptors, One Molecule
If tirzepatide's dual-agonist approach was a breakthrough, retatrutide represents the next leap. Developed by Eli Lilly, retatrutide simultaneously activates three metabolic receptors: GIP, GLP-1, and glucagon. This triple-agonist mechanism is designed to engage synergistic metabolic pathways — the incretin effects of GIP and GLP-1 combined with glucagon's effects on energy expenditure and hepatic lipid metabolism.
Key Takeaway
Retatrutide is the first triple-agonist (GIP + GLP-1 + glucagon) to reach clinical trials. The glucagon receptor component adds energy expenditure and hepatic lipid pathways to the incretin framework.
Why Glucagon?
Adding glucagon receptor activation seems counterintuitive — glucagon raises blood glucose, which appears to work against the goals of metabolic research. But the reality is more nuanced:
- Energy expenditure: Glucagon stimulates thermogenesis and increases basal metabolic rate through hepatic mechanisms
- Hepatic lipid metabolism: Glucagon promotes fatty acid oxidation in the liver, potentially addressing non-alcoholic fatty liver disease (NAFLD) pathways
- Satiety amplification: Glucagon has independent central satiety effects that may complement GLP-1's appetite suppression
The key is the ratio — retatrutide's affinity profile is carefully tuned so that the glucose-lowering effects of GIP and GLP-1 counterbalance glucagon's glucose-raising activity.
Phase 2 Trial Data
Eli Lilly's phase 2 program evaluated retatrutide across multiple dosing tiers over 48 weeks. The trial demonstrated dose-dependent metabolic responses, with higher doses showing effects in weight, HbA1c, and hepatic fat content that exceeded published data from single and dual-agonist peptides.
The Evolution: Single → Dual → Triple
Understanding retatrutide requires seeing it in the context of incretin research evolution:
- Generation 1: GLP-1 agonists (semaglutide) — single receptor, proven efficacy
- Generation 2: GIP/GLP-1 dual-agonists (tirzepatide) — additive incretin effects
- Generation 3: GIP/GLP-1/glucagon triple-agonists (retatrutide) — energy expenditure + incretin + hepatic lipid effects
Available Product
Retatrutide 50mg — ≥98% HPLC verified with Certificate of Analysis.
For research purposes only. Not for human consumption.